Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Docetaxel-Based Induction Chemotherapy in N2/N3 Head and Neck Cancer
2006-002335-24Phase 3Active
- Sponsor
- University of Chicago
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel in head and neck squamous cell carcinoma (HNSCC), head and neck cancer (HNC) and Lymphoepithelioma of the head and neck (LELC) (2 arms), sponsored by University of Chicago. Primary endpoint: Overall survival. Started Jun 2006; status: active.
02
Drugs
docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)Lymphoepithelioma of the head and neck (LELC)
Beyond the preview
Go deeper on 2006-002335-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002335-24.